Tag
API Manufacturing
8 articles
Several Indian pharmaceutical companies reported their fiscal year 2026 results, revealing a mixed performance landscape. Neuland Laboratories demonstrated exceptional growth, with total income and EBITDA surging significantly in the fourth quarter, driven by strong business visibility and investments in peptide manufacturing. Conversely, Cohance Lifesciences experienced a 13% year-over-year revenue decline, although it maintained a healthy adjusted EBITDA margin and a strong balance sheet. Bajaj Healthcare reported robust growth in API exports and increased its regulatory filings, while PAR Drugs saw a substantial drop in net profit. Solara Active Pharma Sciences and Neuland Laboratories have scheduled analyst calls to discuss their financial performance and outlook.
Wanbury TGA Quality Inspection Success at Tanuku
Wanbury's API site in Tanuku successfully passed a quality inspection by Australia's Therapeutic Goods Administration.
Upon receipt of the GMP certificate, the company will be enabled to ship three ad
Anlon Healthcare Q4 FY26 Revenue Up 43% YoY
Anlon Healthcare reported FY26 consolidated revenue growth of 42.98% to INR 172.22 crore and PAT growth of 41.77% to INR 29.09 crore.
Management provided FY27 revenue guidance of INR 380-400 crore and
Concord Biotech FY26 Revenue Declines 12% Amid Challenges
Concord Biotech reported FY26 revenue decline of 12% and PAT drop of 30% due to geopolitical headwinds, supply chain disruptions, and delayed tenders.
The company faced 3-month EU supply restrictions
Natural Capsules Q4 FY26 Revenue Up 55% QoQ
Natural Capsules reported Q4 FY26 consolidated revenue of ₹58.45 crore, up 55% QoQ, with EBITDA recovering to ₹1.33 crore.
Full-year FY26 revenue grew 11% to ₹187.20 crore, but EBITDA was a loss of ₹1
Anlon Healthcare Q4 & FY26 Investor Presentation Highlights
Anlon Healthcare reported FY26 revenue of ₹171.97 crore and PAT of ₹29.09 crore, with EBITDA margin expanding to 27.74%.
The company completed acquisitions of Apiqo Organics and Bizotic Lifescience, a
Supriya Lifescience Q4 FY26 Revenue Hits Record INR277 Crores
Supriya Lifescience reported record Q4 FY26 revenue of INR277 crores, up 50% YoY, and achieved full-year revenue guidance of ~20% growth with INR828 crores.
The company received USFDA EIR with VAI cla
Wanbury FY26 PAT Surges 117% YoY to ₹66.1 Cr
Wanbury reported FY26 PAT growth of 116.6% to ₹66.1 Cr with PAT margin expanding 509 bps to 10.2%.
EBITDA grew 34.9% to ₹107.7 Cr driven by operational efficiencies and favorable product mix.
Company
NGL Fine-Chem Q4 Revenue Jumps 57% YoY to ₹149 Cr
NGL Fine-Chem reported Q4 FY26 revenue of ₹149.23 Cr, a 57% YoY growth, with EBITDA margin expanding 769 bps to 14.35%.
Full-year FY26 PAT grew 128% to ₹48.13 Cr, marking a strong recovery after three